Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2020 May 10.
Published in final edited form as: Clin Trials. 2020 Feb 3;17(2):184–194. doi: 10.1177/1740774520901514

Discordant attitudes and beliefs about cancer clinical trial participation between physicians, research staff, and cancer patients

Grace Clarke Hillyer 1,2, Melissa Beauchemin 2,3,4, Dawn L Hershman 1,2,5, Moshe Kelsen 2, Frances L Brogan 2, Rossy Sandoval 2, Karen M Schmitt 2,3, Andria Reyes 2, Mary Beth Terry 1,2, Andrew B Lassman 2,6, Gary K Schwartz 2,5
PMCID: PMC7211123  NIHMSID: NIHMS1547809  PMID: 32009456

Abstract

Background/Aims:

Essential to bringing innovative cancer treatments to patients is voluntary participation in clinical trials but approximately 8% of American cancer patients are enrolled onto a trial. We used a domain-oriented framework to assess barriers to cancer clinical trial enrollment (CTE).

Methods:

Physicians (MD, DO, fellows, residents) and research staff (physician assistants, nurse practitioners, staff and research nurses, clinical assistants, and program coordinators) involved in clinical research at a comprehensive cancer center completed an online survey in 2017; adult cancer patients not currently enrolled in a trial were interviewed in 2018. To inform the construct of our physician/staff and patient surveys and to assess barriers to clinical trial enrollment, we first conducted in-depth interviews among 14 key informants representing medical, hematologic, gynecologic, neurologic, radiation oncology, as well as members of the clinical research team (one clinical research coordinator, one research nurse practitioner). Perceived structural, provider- and patient-level barriers to CTE were assessed. Differences in perceptions, attitudes and beliefs toward CTE between: 1) physicians and staff, 2) patients by ethnicity, and 3) physicians/staff and patients were examined.

Results:

In total, 120 physicians/staff involved in clinical research (39.2% physicians, 60.8% staff; 48.0% overall response rate) and 150 cancer patients completed surveys. Nearly three-quarters of physician/staff respondents reported difficulty in keeping track of the eligibility criteria for open studies but, was more often cited by physicians than staff (84.4% vs. 64.3%, p = 0.02). Physicians more often reported lack of time to present clinical trial information than did staff (p<0.001); 44.0% of staff vs. 18.2% of physicians reported patient family interaction as a CTE barrier (p=0.007). Hispanic patients more often stated they would join a trial, even if standard therapy was an option compared to non-Hispanic patients (47.7% vs.20.8%, p=0.002). Comparing the beliefs and perceptions of physicians/staff to those of patients, patients more often reported negative beliefs about CTE (e.g. being in a trial does not help patients personally, 32.9% vs. 1.8%, p<0.001) but less often felt they had no other options when agreeing to join (38.1% vs. 85.6%, p<0.001), and less often refused CTE due to lack of understanding (9.1% vs. 63.3%, p=0.001) than reported by physicians/staff.

Conclusions:

Our findings indicate a wide gap between physician/staff and patient attitudes and beliefs about CTE and highlight the importance of focusing future initiatives to raise awareness of this incongruency. Reconciling these differences will require tailored education to reduce implicit biases and dispel misperceptions. Strategies to improve the quality of patient-provider communication and address infrastructure and resource issues are also needed to improve patient enrollment onto cancer clinical trials.

Keywords: Cancer clinical trials, clinical trials participation, patient/provider communication, health education

Background

Cancer clinical trials are a crucial step in advancing cancer treatment, and greater participation in clinical trials expedites these advances with potential to improve the lives of people with cancer. Most cancer patients, however, do not participate in a clinical trial. Recent estimates put overall clinical trial enrollment in the United States at 8%, ranging from 6.3%-7.0% at community centers and 14.0%-15.9% at academic centers.1-3 Although higher than the often cited participation rates of 3%-5%,4-7 participation in clinical trials has changed little over the past few decades.

Barriers to cancer trial enrollment are complex and multifaceted. Several models to understand and address low clinical trial participation have been described, and all propose that barriers at multiple levels effect the phenomenon, specifically at the system, provider, and patient levels,1, 3 as well as the interaction between each of these levels.8, 9 Unger et al. proposed that clinical trial enrollment (CTE) barriers can be categorized as structural (e.g., trial availability), clinical (e.g., patient eligibility), and attitudinal factors (both physician and patient). To address the structural barrier of trial availability, the National Cancer Institute funds cooperative groups to develop trials that are then available across the country through mechanisms that include the NCI-Community Oncology Research Program (NCORP).10 Exclusion of potentially eligible cancer patients due to rigid eligibility criteria,11, 12 particularly individuals from underrepresented age, gender, and racial/ethnic groups for many clinical trials where representation is disproportionately low,13 is an issue that is currently under evaluation by the American Society of Clinical Oncology.14 For example ethnic and racial minorities make up 38.7% of the U.S. population15 but only make up 2-16% of those enrolled in American cancer clinical trials,13, 15, 16 with 0.1% are American Indian, 2.2% Hispanic, 3.3% Asian, and 6.1% Black/African American.17 This, however, conflicts with reports indicating that racial and ethnic minority patients are as willing as whites to participate in health research and clinical trials.18, 19 Much research has focused on addressing patient-related barriers as ultimately patients make the final decision whether or not to participate in a clinical trial.2, 20-22 Interventions targeted toward patients alone, however, have variable effect; flexible and multi-faceted strategies that address both patients and providers were found to be more effective.23

Although, substantial work has been done to understand barriers to clinical trial participation, few studies have specifically targeted minority participation using a domain-oriented framework that includes an evaluation of provider and patient attitudes. Minorities represent 33% of all cancer patients seeking care at our large, urban NCI-Comprehensive Cancer Center and Minority Underserved NCI-Community Oncology Research Program (MU-NCORP) site,24 21% of whom are Hispanic. However, the proportion of Hispanics in our catchment area is even higher at 27.4%, ranging from 17.0% in Rockland County to 55.4% in the Bronx, New York. Our most recent efforts to increase minority CTE based on the Accrual to Clinical Trial framework25 included hiring a bilingual clinical trials navigator and conducting awareness campaigns to educate providers and patients. These efforts are expected to increase accrual to clinical trials, specifically among minority patients; however, minority CTE continues to be a challenge.

To identify actionable factors to increase CTE among of minority patients in general and Hispanic patients specifically, we examined the structural, and physician, and patient attitudinal barriers to cancer clinical trial participation among the providers and diverse groups of patients with cancer at our site. We also evaluated the knowledge and attitudes about clinical trials as well as perceptions about the barriers to clinical trial enrollment among key clinical personnel engaged in the conduct of cancer clinical trials and among a racially/ethnically diverse cancer patient population.

Methods

Setting and subjects

All procedures were conducted at a large urban Minority-Underserved NCORP site Columbia University Irving Medical Center (CUIMC). Physicians involved in clinical research and trial staff were identified from Cancer Center membership rosters. Cancer patient participants were recruited at medical, gynecologic, neurologic, and hematologic oncology clinics. Included were patients who were under the care of a cancer center clinical oncologist and were not currently enrolled in a clinical trial. Those not yet diagnosed with cancer or who were seeking second opinions regarding diagnosis were excluded. Participants were interviewed in the language of their preference (English or Spanish) by bilingual research team members. All procedures were approved by the CUIMC Institutional Review Board.

Development of physician, staff, and patient surveys

To inform the construct of our physician/staff and patient surveys and to assess barriers to clinical trial enrollment, we first conducted in-depth interviews among 14 key informants representing medical, hematologic, gynecologic, neurologic, radiation oncology, as well as members of the clinical research team (one clinical research coordinator, one research nurse practitioner). Key informants provided insight to successful strategies to increase accrual such as methods to identify potential participants, the importance of bilingual staff, and the development of a pervasive trials-friendly culture. Barriers identified included: space and time constraints; need for increased coordinator support; desire for certain disease-specific trials; and perceived poor communication between oncology groups and subspecialties.

Physicians and staff survey procedures

The physician and staff surveys were conducted August through September 2017. An email invitation addressed from the Chief of the division of hematology/oncology (GS) was distributed to 250 physicians (MD, DO, fellows, and residents), clinical and research staff (physician assistants, nurse practitioners, staff and research nurses, clinical assistants, and program coordinators). A brief introduction to the study was included along with a unique link to a web-based informed consent and survey in Qualtrics. Consent and survey responses were uploaded via a secure internet connection. Reminders were sent twice at one-week intervals for non-respondents.

The survey was developed based on a review of the literature and the key informant interviews. Prior to implementation, the feasibility of survey administration was tested among a sample of research coordinators and was found to be acceptable. The survey took approximately 8 minutes to complete. Structural barriers encountered in cancer clinical trial enrollment26 and personal positive and negative attitudes toward clinical trials26-28 were assessed. Perceived reasons why, from the participant’s (clinical researcher/staff) perspective, cancer patients enroll in clinical trials29 and decline participation were determined.26-28 Reasons for study refusal were grouped as patient-related, psychosocial, logistic, and trial-related factors, and financial concerns based on categories identified in the literature.

Patient survey procedures

We used a convenience sampling strategy to approach adult cancer patients, aged 18 years and older in oncology clinic waiting rooms over a 6 month period. Patients who were under the care of a physician from the institution and who were not currently participating in a clinical trial were considered eligible to participate in this study. Surveys were conducted in the language preferred by the participant (English or Spanish) in a private area or examination room by bilingual research team members. Language in which the survey was conducted was recorded. Demographic information including age, gender, race/ethnicity, educational level, and marital status was collected. Health literacy was determined using a brief literacy screener30 and awareness of clinical trials was evaluated by asking a single question “Do you know what a clinical trial is?” with responses recorded as “Yes/No.” Patient participants were asked if a clinical trial was ever offered to them and, if so, did they participate along with reasons for joining29 or declining.26-28 These questions, as well as questions regarding personal attitudes and beliefs toward clinical trials, mirrored questions asked of the physicians and staff. Lastly, a series of five questions to ascertain the circumstances under which a patient would consider joining a clinical trial were posed to patient participants (e.g., “If you had tried all available standard treatment but it did not work, would you consider participating in a clinical trial for a new treatment?”).

Data analysis

Descriptive analyses including frequency distributions, and mean, standard deviation, median, and range for continuous variables. Univariable tests of association using the Chi square test were performed to assess differences in categorical type questions and Student’s t test for continuous variables between physicians and clinical research staff and between Hispanic and non-Hispanic cancer patients. Comparison between positive and negative clinical trial attitudes, and reasons for clinical trial participation and declination as perceived by physicians /staff vs. cancer patients was conducted using Chi square test. P values <0.05 were considered statistically significant and all analyses were performed using IBM SPSS (version 24).31 All procedures were reviewed and approved by the Columbia University Medical Center Institutional Review Board.

Results

Surveys were distributed to 115 physicians and 135 clinical/research staff involved in the conduct of clinical trials. Of these, 161 responses were received (response rate = 64.4%; 79/115 = 68.7% physicians and 82/135 = 60.7% clinical/research staff). Duplicates and surveys with ≥50% missing data were removed, resulting in 120 surveys for analysis; 47 physicians (39.2%) and 73 (60.8%) clinical/research staff. A total of 150 cancer patients completed interviews; 98 (65.3%) were non-Hispanic and 44 Hispanic (29.3%).

Physician and staff responses

Nearly three-quarters (n = 74, 73.3%) of respondents reported difficulty in keeping track of the eligibility criteria for open studies (Table 1). This was more often cited by physicians than staff (84.4% vs. 64.3%, p = 0.02). Other barriers included complicated paperwork (n = 55, 54.5%), difficulty in communicating complex information to patients (n = 56, 57.1%), and patients refusing placebo (n = 43, 51.8%). While overall only 31.9% of respondents found interacting with the patient’s family to be a barrier to enrollment, staff twice as often as physicians (44.0% vs. 18.2%, p = 0.007) reported this barrier. Conversely, physicians twice as often as research staff found making time to discuss clinical trials with patients during office visits to be difficult (67.4% vs. 34.0%, p = 0.001).

Table 1.

Structural barriers encountered by physicians and staff enrolling cancer patients onto clinical trials (n = 120), September - November 2017.

Total
N = 120
Physicians
N = 47
Staff
N = 73
P value
N (%) N (%) N (%)
Administrative
 Paperwork is very complicated 55 (54.5) 26 (57.8) 29 (51.5) 0.55
 Lack of support staff to assist with enrollment 47 (45.6) 24 (52.2) 23 (40.4) 0.23
 Enrollment process is too time consuming 48 (49.0) 26 (56.5) 22 (42.3) 0.16
 Difficult to keep track of the eligibility criteria 74 (73.3) 38 (84.4) 36 (64.3) 0.02
Patient-related
 Patients frequently miss scheduled
Appointments
35 (35.7) 14 (32.6) 21 (38.2) 0.56
 Patients refuse placebo 43 (51.8) 20 (50.0) 23 (53.5) 0.75
 Interacting with the patient’s family 30 (31.9) 8 (18.2) 22 (44.0) 0.007
 Minority patients are difficult to enroll 28 (30.8) 12 (28.6) 16 (32.7) 0.67
Process-related
 Very few eligible patients 45 (46.9) 22 (51.2) 23 (43.4) 0.45
 Clinical trial protocols are too rigid 36 (35.0) 16 (34.8) 20 (35.1) 0.97
 Too difficult to match patients to trials 24 (28.2) 13 (31.7) 11 (25.0) 0.49
 Lack of minority physicians to recruit minority patients 40 (43.0) 20 (45.5) 20 (40.8) 0.65
 Making time to discuss clinical trials with patients during office visits 47 (50.5) 31 (67.4) 16 (34.0) 0.001
 Translating documents into Spanish and other languages is difficult and expensive 42 (44.7) 21 (48.8) 21 (41.2) 0.46
 Communicating complex information to patients is very difficult 56 (57.1) 26 (56.5) 30 (57.7) 0.91
 No space to enroll and consent patients 30 (30.6) 13 (28.3) 17 (32.7) 0.63
 Heavy clinical patient volume 32 (35.6) 20 (44.4) 12 (26.7) 0.08

Patient responses

The majority of cancer patient surveys were conducted in English (78.0%); most participants were female (59.3%), White (61.3%), and non-Hispanic (70.7%) (Table 2). Approximately one-quarter did not know what a clinical trial is and only 21.3% had ever been invited to participate in a trial; of those, 66% joined the trial (14.0% of all participants). When asked about circumstances under which they would “definitely” participate in a clinical trial, only 24% stated that would join today if asked. The highest proportion of participants (72.7%) would “definitely” consider a clinical trial if they thought their cancer was incurable and the clinical trial offered a new treatment, followed by 66.0% who would “definitely” consider a trial of a new treatment if all available treatment had failed.

Table 2.

Cancer patient clinical trials knowledge, attitudes and beliefs by ethnicity (n = 150), May – Sept 2018

Total
(n = 150)
Non-
Hispanic
(n = 106)
Hispanic
(n = 44)
p
N (%) N (%) N (%)
Survey language <0.001
 English 117 (78.0) 104 (98.1) 13 (29.5)
 Spanish 33 (22.0) 2 (1.9) 31 (70.5)
Demographics
Gender 0.97
 Male 61 (40.7) 43 (40.6) 18 (40.9)
 Female 89 (59.3) 63 (59.4) 26 (59.1)
Age
 Mean [SD] 61.5 [14.1] 61.7 [14.7] 61.0 [12.5] 0.79
 Median 64.0 63.5 64.0
 Range 27-96  27-96 28-82
Hispanic/Latino --
 Yes 44 (29.3) 0 (0.0) 44 (100.0)
 No 106 (70.7) 106 (100.0) 0 (0.0)
Race
 African American/Afro Caribbean/African/Black 20 (13.3) 13 (12.3) 7 (15.9) 0.63
 American Indian/Alaskan Native 0 (0.0) 0 (0.0) 0 (0.0) --
 Asian/Pacific Islander 8 (5.3) 8 (7.5) 0 (0.0) 0.11
 White 92 (61.3) 82 (77.4) 10 (22.7) <0.001
 Mixed race 25 (16.7) 3 (2.8) 22 (50.0) <0.001
 Other 6 (4.0) 1 (0.9) 5 (11.4) 0.009
Education <0.001
 No formal education 0 (0.0) 0 (0.0) 0 (0.0)
 Grade 1-8 16 (10.7) 3 (2.8) 13 (29.5)
 Grade 9-12 34 (22.7) 16 (15.1) 16 (40.9)
 Some college 22 (14.7) 14 (13.2) 8 (18.2)
 College 32 (21.3) 28 (26.4) 4 (9.1)
 Graduate degree 46 (30.7) 45 (42.5) 1 (2.3)
Marital status 0.56
 Married/living as married 89 (59.3) 65 (61.3) 24 (54.5)
 Single 34 (22.7) 25 (23.6) 9 (20.5)
 Divorced/separated 18 (12.0) 11 (10.4) 7 (15.9)
 Widowed 9 (6.0) 5 (4.7) 4 (9.1)
Health literacy
How often do you understand information from your physician 0.49
 Never 1 (0.7) 1 (0.9) 0 (0.0)
 Almost never 0 (0.0) 0 (0.0) 0 (0.0)
 Sometimes 37 (24.7) 24 (22.6) 13 (29.5)
 All the time 112 (74.7) 81 (76.4) 31 (70.5)
How often do you need help with instructions and information from your physician or pharmacy <0.001
 Never 77 (51.7) 64 (61.0) 13 (29.5)
 Almost never 25 (16.8) 21 (20.0) 4 (9.1)
 Sometimes 37 (24.8) 17 (16.2) 20 (45.5)
 All the time 10 (6.7) 3 (2.9) 7 (15.9)
Clinical trials knowledge and participation
Know what a clinical trial is <0.001
 Yes 110 (73.3) 89 (84.0) 21 (47.7)
 No 40 (26.7) 17 (16.0) 23 (52.3)
Ever invited to participate in a clinical trial
 Yes 32 (21.3) 27 (25.5) 5 (11.4) 0.055
 No 118 (78.7) 79 (74.5) 39 (88.6)
Join the trial 0.46
 Yes 21 (14.0) 17 (63.0) 4 (80.0)
 No 11 (7.3) 10 (37.0) 1 (20.0)
Circumstances under which participation would be considered
If you were asked to participate in a CT today, would you participate 0.05
 Yes, I definitely would 36 (24.0) 20 (18.9) 16 (36.4)
 I might, not sure, it depends 97 (64.7) 75 (70.8) 22 (50.0)
 No, I definitely would not 17 (11.3) 11 (10.4) 6 (13.6)
If you tried all available standard treatment but it did not work, would you consider participating in a CT for a new treatment 0.56
 Yes, I definitely would 99 (66.0) 72 (67.9) 27 (61.4)
 I might, not sure, it depends 47 (31.3) 32 (30.2) 15 (34.1)
 No, I definitely would not 4 (2.7) 2 (1.9) 2 (4.5)
If you thought your cancer was incurable, would you consider participating in a CT for a new treatment 0.12
 Yes, I definitely would 109 (72.7) 78 (73.6) 31 (70.5)
 I might, not sure, it depends 35 (23.3) 26 (24.5) 9 (20.5)
 No, I definitely would not 6 (4.0) 2 (1.9) 4 (9.1)
If you thought your cancer could be cured with standard treatment, would you consider participating in a CT of a new treatment that may or may not be better 0.002
 Yes, I definitely would 43 (28.7) 22 (20.8) 21 (47.7)
 I might, not sure, it depends 78 (52.0) 64 (60.4) 14 (31.8)
 No, I definitely would not 29 (19.3) 20 (18.9) 9 (20.5)
If you were offered participation in a CT and there was an equal chance you would either receive standard treatment or a new treatment, would you consider participating in that CT 0.003
 Yes, I definitely would 48 (32.0) 25 (23.6) 23 (52.3)
 I might, not sure, it depends 85 (56.7) 67 (63.2) 18 (40.9)
 No, I definitely would not 17 (11.3) 14 (13.2) 3 (6.8)

Hispanics were more likely to state that they did not know what a clinical trial is compared with non-Hispanic patients (52.3% vs. 16.0%, p <0.001), but were as likely as non-Hispanics to report being invited to participate in a clinical trial (11.4% vs. 25.5%, p = 0.055). However, when asked if they would participate in a clinical trial today if asked, 36.4% of Hispanic patients vs. 18.9% non-Hispanic patients responded they would (p = 0.05) and twice as often responded “I definitely would” to joining a clinical if they thought their cancer could be cured with standard treatment but were offered a new treatment that may or may not better (47.7% vs. 20.8%, p = 0.002) and if there was an equal chance of receiving either the standard treatment or the experimental treatment in a trial (52.3% vs. 23.6%, p = 0.003) than non-Hispanic patients.

Few physicians and staff (20.7%) agreed that clinical trials absolutely provide the best treatment available, and less than half (43.9%) believed that the benefits of clinical trial participation outweighed any risks or harms. However, 57.0% felt that being in a clinical trial helps a patient be more in control of their disease and treatment (Table 3). One quarter of physicians and staff believed that patients enroll in clinical trials as a last resort. Researchers and staff perceived the most common reasons for patients to enroll in trials were to get better treatment (93.9%), to get the newest treatment available (92.2%), and because the patient had no better options (85.6%). The most frequently cited reasons for declining a trial perceived by researchers and staff were concern about randomization or getting a placebo (70.8%), followed by mistrust of the medical system, science, or researchers (69.2%).

Table 3.

Comparison of clinical trial attitudes and reasons for participation or declination of clinical trial offers as perceived by physicians and staff and reported by cancer patients.

Physician/staff
N = 120
Patient
N = 150
P value
Clinical trial attitudes
Positive attitudes N (%) N (%)
 Being part of a clinical trial helps patients be more in control of their disease and treatment 65 (57.0) 104 (69.3) 0.04
 A clinical trial absolutely provides the best treatment available 24 (20.7) 90 (60.0) <0.001
 The benefits to patients of being in a clinical trial outweigh any risks or harms 50 (43.9) 85 (57.0) 0.03
 Clinical trials are important to the advancement of medical science and clinical cancer care 115 (99.1) 148 (98.7) 0.72
Negative attitudes
 Clinical trials are only offered to people whose disease is hopeless 10 (8.7) 41 (27.3) <0.001
 Being in a clinical trial does not help patients personally 2 (1.8) 49 (32.9) <0.001
 Patients who enroll in a clinical trial are gambling with their life 13 (11.3) 31 (20.8) 0.04
 Doctors only offer clinical trials as a last resort 14 (12.2) 35 (23.5) 0.019
 Patients enroll in clinical trials as a last resort 29 (25.4) 36 (24.0) 0.79
 Clinical trials are only good for the doctors, not for the patients 5 (4.3) 20 (13.4) 0.013
Reasons to participate in a clinical trial N = 21
 To get better treatment 108 (93.9) 20 (95.2) 1.00
 Help people in the future 92 (80.0) 18 (85.7) 0.76
 To get newest treatment available 107 (92.2) 19 (90.5) 0.68
 Doctor recommended it 100 (84.0) 19 (90.5) 0.74
 Family wanted it 56 (50.0) 7 (33.3) 0.07
 Wanted a better chance at a cure 94 (80.3) 20 (95.2) 0.12
 Had no better options 101 (85.6) 8 (38.1) <0.001
Reasons to decline participation in a clinical trial N = 11
Patient-related factors
  Language/cultural barriers 69 (57.5) 3 (27.3) 0.052
  Religious reasons 27 (22.5) 0 (0.0) 0.021
  Lack of understanding about research trials 76 (63.3) 1 (9.1) 0.001
  Lack of interest in clinical trials 41 (34.2) 4 (40.0) 0.71
Psychosocial factors
  Mistrust of the medical system/science/Researchers 83 (69.2) 4 (36.4) 0.043
  Feeling physically or emotionally Overwhelmed 77 (64.2) 2 (18.2) 0.003
Logistic factors
  Inconvenience 71 (59.2) 3 (27.3) 0.04
  Lack of transportation 54 (45.0) 4 (36.4) 0.75
  Family/personal responsibilities 43 (35.8) 2 (18.2) 0.33
Trial-related factors
  Invasive procedures 50 (41.7) 1 (9.1) 0.02
  Concerns about toxicity 72 (60.0) 2 (18.2) 0.006
  Concerns about randomization or getting a placebo 85 (70.8) 3 (27.3) 0.005
  Preference for a proven treatment 69 (57.5) 5 (45.5) 0.53
Financial concerns
  Lack of insurance coverage 35 (29.2) 1 (9.1) 0.29
  Additional out-of-pocket costs 44 (36.7) 2 (18.2) 0.33

Comparison of results among physicians, staff and patients

Comparison of the perceptions of the physicians and staff to patient attitudes showed that more often, patients endorsed a positive attitude about trial involvement, differing significantly from the views of the physicians and staff (Table 3). Patients more often agreed that the benefits of participation outweigh the risks or harms (57.0% vs. 43.9%, p = 0.03). In addition, patients also more frequently reported negative attitudes toward clinical trials, many of which diverged significantly from the perceptions of physicians and staff. Patients more often than researchers believed that clinical trials are only offered to people whose disease is hopeless (27.3% vs. 8.7%, p <0.001), that being in a clinical trial does not help patients personally (32.9% vs. 1.8%, p <0.001), that enrolling in a clinical trial is gambling with their life (20.8% vs. 11.3%, p = 0.04), and that clinical trials are offered as a last resort (23.5% vs. 12.2%, p 0.019).

Of patients offered a clinical trial and who agreed to participate (n = 21), opinions differed from those of the physicians and staff with 38.1% of patients who stated that having no better options was a consideration when making their decision to join compared to 85.6% of physicians who believed this was an important consideration for patients (p <0.001). Among patients who were offered participation in a clinical trial but declined (n = 11), most frequent reasons for this choice were preference for a proven treatment (45.5%), lack of interest (40.0%). Reasons for declining participation cited by patients also varied significantly from those perceived by physicians and staff. For example, physicians/staff more often believed that patients decline clinical trial participation because of language and cultural barriers (57.5% vs. 27.3%, p <0.001), lack of understanding about clinical trials (63.3% vs. 9.1%, p = 0.001), and mistrust of the medical system (69.2% vs. 36.4%, p = 0.043) compared to patient report. Patients also less often reported declining participation because of invasive procedures (9.1% vs. 41.7%, p = 0.02), concerns about toxicity (18.2% vs. 60.0%, p = 0.006), and reluctance to be randomized or to receive a placebo (27.3% vs. 70.8%, p = 0.005).

Discussion

Our findings demonstrate barriers to trial participation are frequent at the structural, provider, and patient levels. Additionally, we found significant differences in perceived patient barriers to trial enrollment between research physicians and their staff; differences in barriers, attitudes and beliefs between Hispanic and non-Hispanic patients; and, most importantly, differences between what research physicians and staff believe are barriers for patients and what patients report as barriers.

The process of enrolling a cancer patient onto a clinical trial is multifaceted with the potential for breakdown at several key junctures along the way. Typically, patients newly diagnosed with cancer visit a cancer clinic and, depending on site infrastructure and protocols, are evaluated for trial eligibility. Assessment of eligibility, however, is contingent upon the availability of trials for the particular histology or stage of a patient’s cancer.3 In a recent systematic review and meta-analysis of multi-level clinical trials barriers, Unger et al. reported that structural barriers are perhaps the greatest of barriers to trial participation; clinical trials were not available for 55.6% of cancer patients and another 2.15% were ineligible for trials that were available.32 The structural barriers identified in our study that included difficulty in keeping track of eligibility criteria and carving out time during a visit to discuss trials and enrollment further complicate the first crucial step in the process of enrolling patients to clinical trials.

Once assessed as eligible for an available trial, the physician may or may not choose to discuss and offer trial enrollment to the patient. Physician bias and its impact on the decision whether or not offer a given patient a clinical trial has not been fully investigated. One example is a study conducted by Kornblith et al. that examined physician perceptions of barriers to clinical trials among elderly breast cancer patients. Physicians reported reluctance to enroll elderly patients due to comorbid conditions not excluded by trial protocol; that elderly patients would not fully understand trial procedures and would therefore likely be non-compliant; and that older patients may experience greater toxicity.33 Others have similarly reported how conscious and unconscious implicit physician bias against a patient’s age and comorbidities as well as bias against members of minority groups and perceptions of patient mistrust of researchers.17 These biases sometimes result in spontaneous and reflexive decisions about the candidacy of a patient for a trial, influence patient-provider interactions and lead to foregoing clinical trial options during discussions about treatment thus limiting offers of enrollment.17, 34, 35 Physician bias may also contribute to poor accrual to trials and early trial closure in addition to the lost opportunity to provide new treatments and better ancillary patient care.3, 17

Only at the end of this process of negotiating structural and provider-level barriers does the patient’s decision to participate enter the equation. Patients in our study more frequently endorsed negative attitudes about clinical trials, such as only being offered to those whose disease is hopeless, not helping patients personally, participation is gambling with one’s life, and only being good for the doctor, not the patient. Consistent with prior literature, a significant number of patients cited a preference for standard treatment or a lack of interest in participating in clinical research as a reason for declining.36 Furthermore, our results demonstrate a significant difference in clinical trial knowledge and attitudes by ethnicity, with Hispanics reporting less awareness about clinical trials which is consistent with previously literature reporting lower participation in clinical trials in racial and ethnic minority groups.37 We also found that, despite less awareness of clinical trials and greater reported negative attitudes toward trials, Hispanic patients were more willing to consider a trial than their non-Hispanic counterparts were. When posed hypothetical conditions under which a patient might consider clinical trial participation, only a small proportion of patients overall stated that they definitely would not participate with Hispanics twice as often stating they would definitely participate. These findings are aligned with those of Comis et al. who reported that most Americans hold favorable views of clinical trial participation.19

Discordance between what physicians and research staff perceive as barriers and what patients state has not been previously reported. In our study, physicians and research staff often over- and under-estimated the importance of patient-reported barriers and highlight the ongoing communication that is needed between the provider/staff and patient. A study by Albrecht et al. of videotaped outpatient interactions between oncologists and patients and their family, when present, at two comprehensive cancer centers found that clinical trial participation was only offered to 20% of participants previously determined to be eligible for a trial, but when offered, 75% of these eligible patients assented. Greater shared conversation control with the physician was significantly related to the patient’s decision to enroll highlighting the importance of content and relational communication between physicians and patients, provider-patient alliance building, and supportive dialogue in a full, clear, and open discussion of clinical trial participation.38

Our study had some strengths worth highlighting. First, we developed the survey from key informant interviews which revealed key structural and provider-related topics that we included in our quantitative survey. This participatory research process ensured that we were asking relevant questions related to the topic. However, we did not include a patient representative in the development of our survey; this would have strengthened our study further. This is a single site, observational study conducted at a large urban Minority-Underserved NCORP site within an NCI-designated comprehensive cancer center in New York City, which may limit generalizability of our findings to other geographic areas and patient populations. A major strength of this study is the unique assessment of the knowledge, attitudes, and beliefs of physicians and staff in parallel with those of patients. This allows us to have greater insight into the individual groups, but also to better develop tailored interventions within appropriate groups. Tailored, multi-level interventions have been cited as the most successful to reduce barriers to clinical trial enrollment, and the level of granularity and comparison that our data provides will support future initiatives.

Conclusion

Our study highlights the knowledge, attitudes, and beliefs about clinical trial enrollment from provider, staff, and patient perspectives and support previously defined barriers to clinical trial participation, specifically between Hispanic and non-Hispanic groups. These data also provide new information about the gaps between provider/staff- and patient-perceived barriers. Specifically, to our knowledge, this is the first published comprehensive assessment across physicians, staff, and patients to understand differences in perceptions about clinical trial enrollment barriers. Attitudes can be defined as a “learned tendency to evaluate things in a certain way” that are informed by personal experience, social norms, conditioning and observation.39 Differences in attitudes between providers and patients are important to understand in order to focus future initiatives to raise awareness about incongruency between each group and reduce implicit biases. One possible strategy to address discordant provider/patient attitudes could be to incorporate these same factors that lead to the development of attitudes into educational interventions to effect attitude change. For example, enhancing personal clinical trial enrollment experiences for patients and providers through improved communication and streamlined workflow or promoting the enrollment of racial and ethnic minorities onto clinical trials as an institution-wide desired social norm. Clear, transparent communication between providers, staff, and patients about clinical trials should also be emphasized, as this will help to reduce inconsistencies across provider/patient continuum and in addition, help to reduce medical mistrust.40 Other strategies such as educating patients about clinical trials prior to their first oncology visit,41 engaging the community, diversifying the clinical and research staff to be more representative of the community, and providing education to the community and providers/staff may also help to reduce these barriers.40

Acknowledgements:

This study was supported by a National Cancer Institute Minority/ Underserved Community Oncology Research Program (MU/NCORP), UM1 CA189960.

References

  • 1.American Cancer Society Cancer Action Network. Barriers to patient enrollment in therapeutic clinical trials for cancer: A landscape report, https://www.fightcancer.org/sites/default/files/National%20Documents/Clinical-Trials-Landscape-Report.pdf (2018, accessed 4 March 2019).
  • 2.Lara PN Jr, Higdon R, Lim N, et al. Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrollment. J Clin Oncol 2001; 19: 1728–1733. [DOI] [PubMed] [Google Scholar]
  • 3.Unger JM, Vaidya R, Hershman DL, et al. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. JNCI 2019; 111: 245–255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Hallquist Viale P. Participation in cancer clinical trials: researching the causes of low accrual. J Adv Pract Oncol 2016; 7: 143–144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Unger JM, Barlow WE, Martin DP, et al. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. JNCI 2014; 106: dju002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Weber JS, Levit LA, Adamson PC, et al. American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment. J Clin Oncol 2015; 33: 278–284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Friedman MA and Cain DF. National Cancer Institute sponsored cooperative clinical trials. Cancer 1990; 65: 2376–2382. [DOI] [PubMed] [Google Scholar]
  • 8.Durant RW, Wenzel JA, Scarinci IC, et al. Perspectives on barriers and facilitators to minority recruitment for clinical trials among cancer center leaders, investigators, research staff, and referring clinicians: enhancing minority participation in clinical trials (EMPaCT). Cancer 2014; 120 Suppl 7: 1097–1105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Mills EJ, Seely D, Rachlis B, et al. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol 2006; 7: 141–148. [DOI] [PubMed] [Google Scholar]
  • 10.Piana R. The evolution of U.S. cooperative group trials: Publicly funded cancer research at a crossroads, https://www.ascopost.com/issues/march-15-2014/the-evolution-of-us-cooperative-group-trials-publicly-funded-cancer-research-at-a-crossroads/ (2019, accessed 23 September 2019).
  • 11.Kennedy-Martin T, Curtis S, Faries D, et al. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials 2015; 16: 495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Van Spall HGC, Toren A, Kiss A, et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 2007; 297: 1233–1240. [DOI] [PubMed] [Google Scholar]
  • 13.Kwiatkowski K, Coe K, Bailar JC, et al. Inclusion of minorities and women in cancer clinical trials, a decade later: Have we improved? Cancer 2013; 119: 2956–2963. [DOI] [PubMed] [Google Scholar]
  • 14.Inclusion/exclusion criteria for National Cancer Institute (NCI) sponsored clinical trials: NCI recommended protocol text and guidance based on joint recommendations of the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research (Friends), https://ctep.cancer.gov/protocolDevelopment/docs/NCI_ASCO_Friends_Eligibility_Criteria.pdf (2018, accessed 23 September 2019).
  • 15.Williams SL. Overcoming the barriers to recruitment of underrepresented minorities. Clinical Researcher 2018; 32. [Google Scholar]
  • 16.Parra A, Karnad AB and Thompson IM. Hispanic accrual on randomized cancer clinical trials: a call to arms. J Clin Oncol 2014; 32: 1871–1873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Hamel LM, Penner LA, Albrecht TL, et al. Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer. Cancer Control 2016; 23: 327–337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Wendler D, Kington R, Madans J, et al. Are racial and ethnic minorities less willing to participate in health research? PLoS Med 2006; 3: e19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Comis RL, Miller JD, Aldige CR, et al. Public attitudes toward participation in cancer clinical trials. J Clin Oncol 2003; 21: 830–835. [DOI] [PubMed] [Google Scholar]
  • 20.Byrne MM, Tannenbaum SL, Gluck S, et al. Participation in cancer clinical trials: why are patients not participating? Med Decis Making 2014; 34: 116–126. [DOI] [PubMed] [Google Scholar]
  • 21.Meropol NJ, Buzaglo JS, Millard J, et al. Barriers to clinical trial participation as perceived by oncologists and patients. J Natl Compr Canc Netw 2007; 5: 655–664. [DOI] [PubMed] [Google Scholar]
  • 22.Mills EJ, Seely D, Rachlis B, et al. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol 2006; 7: 141–148. [DOI] [PubMed] [Google Scholar]
  • 23.Heller C, Balls-Berry JE, Nery JD, et al. Strategies addressing barriers to clinical trial enrollment of underrepresented populations: a systematic review. Contemp Clin Trials 2014; 39: 169–182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.National Cancer Institute. National Cancer Institute Community Oncology Research Program: About NCORP, https://ncorp.cancer.gov/about/ (2018, accessed 9 February 2019).
  • 25.Paskett ED, Katz ML, DeGraffinreid CR, et al. Participation in cancer trials: recruitment of underserved populations. Clin Adv Hematol Oncol 2003; 1: 607–613. [PubMed] [Google Scholar]
  • 26.Boden-Albala B, Carman H, Southwick L, et al. Examining barriers and practices to recruitment and retention in stroke clinical trials. Stroke 2015; 46: 2232–2237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Penberthy L, Brown R, Wilson-Genderson M, et al. Barriers to therapeutic clinical trials enrollment: differences between African-American and white cancer patients identified at the time of eligibility assessment. Clin Trials 2012; 9: 788–797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Quinn GP, McIntyre J, Gonzalez LE, et al. Improving awareness of cancer clinical trials among Hispanic patients and families: audience segmentation decisions for a media intervention. J Health Commun 2013; 18: 1131–1147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Cullen T. 16 reasons why people join clinical trials. Imperial Blog. ImperialCRS.com, 2015. [Google Scholar]
  • 30.Chew LD, Bradley KA and Boyko EJ. Brief questions to identify patients with inadequate health literacy. Fam Med 2004; 36: 588–594. [PubMed] [Google Scholar]
  • 31.IBM Corp. IBM SPSS Statistics for Windows, Version 24.0 Armonk, NY: IBM Corp., 2016. [Google Scholar]
  • 32.Unger JM, Vaidya R, Hershman DL, et al. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. J Natl Cancer Inst 2019; 111: 245–255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Kornblith AB, Kemeny M, Peterson BL, et al. Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer 2002; 95: 989–996. [DOI] [PubMed] [Google Scholar]
  • 34.Howerton MW, Gibbons MC, Baffi CR, et al. Provider roles in the recruitment of underrepresented populations to cancer clinical trials. Cancer 2007; 109: 465–476. [DOI] [PubMed] [Google Scholar]
  • 35.McCaskill-Stevens W, Pinto H, Marcus AC, et al. Recruiting minority cancer patients into cancer clinical trials: a pilot project involving the Eastern Cooperative Oncology Group and the National Medical Association. J Clin Oncol 1999; 17: 1029–1039. [DOI] [PubMed] [Google Scholar]
  • 36.Germain DS, Denicoff AM, Dimond EP, et al. Use of the National Cancer Institute Community Cancer Centers Program screening and accrual log to address cancer clinical trial accrual. J Oncol Pract 2014; 10: e73–e80. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Kwiatkowski K, Coe K, Bailar JC, et al. Inclusion of minorities and women in cancer clinical trials, a decade later: Have we improved? Cancer 2013; 119: 2956–2963. [DOI] [PubMed] [Google Scholar]
  • 38.Albrecht TL, Eggly SS, Gleason MEJ, et al. Influence of clinical communication on patients' decision making on participation in clinical trials. J Clin Oncol 2008; 26: 2666–2673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Cherry K. Attitudes and behavior in psychology, https://www.verywellmind.com/attitudes-how-they-form-change-shape-behavior-2795897 (2019, accessed 6 November 2019).
  • 40.Heller C. Strategies addressing barriers to clinical trial enrollment of underrepresented populations: a systematic review. Contemp Clin Trials 2014; 39: 169–182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Meropol NJ, Wong YN, Albrecht T, et al. Randomized trial of a web-based intervention to address barriers to clinical trials. J Clin Oncol 2016; 34: 469–478. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES